An Expanded Access Program for SYN023 in Rabies Treatment
ConditionRabies
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorSynermore Biologics (Suzhou) Co., Ltd.
About this trial
This sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected life-threatening rabies lacking adequate alternative therapies.
Eligibility criteria
Qualifiers
Must be ineligible for or lack access to other investigational or approved therapies
Must have no available alternative curative treatment options
Disqualifiers
None
Trial design
Treatments tested in this trial
- Zamerovimab and Mazorelvimab Injection
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov